Abstract:The chemokine receptor CXCR4 has become an attractive therapeutic target for HIV-1 infection, hematopoietic stem cell mobilization, and cancer metastasis. A wide variety of synthetic antagonists of CXCR4 have been developed and studied for a growing list of clinical applications. To compare the biological effects of different antagonists on CXCR4 functions and their common and/or distinctive molecular interactions with the receptor, we conducted head-to-head comparative cell-based biological and mutational analyses of the interactions with CXCR4 of eleven reported antagonists, including HC4319, DV3, DV1, DV1 dimer, V1, vMIP-II, CVX15, LY2510924, IT1t, AMD3100, and AMD11070 that were representative of different structural classes of D-peptides, L-peptide, natural chemokine, cyclic peptides, and small molecules. The results were rationalized by molecular modeling of CXCR4-antagonist interactions from which the common as well as different receptor binding sites of these antagonists were derived, revealing a number of important residues such as W94, D97, H113, D171, D262, and E288, mostly of negative charge. To further examine this finding, we designed and synthesized new antagonistic analogs by adding positively charged residues Arg to a D-peptide template to enhance the postulated charge-charge interactions. The newly designed analogs displayed significantly increased binding to CXCR4, which supports the notion that negatively charged residues of CXCR4 can engage in interactions with moieties of positive charge of the antagonistic ligands. The results from these mutational, modeling and new analog design studies shed new insight into the molecular mechanisms of different types of antagonists in recognizing CXCR4 and guide the development of new therapeutic agents.

Progress in Studies of Structure, Mechanism and Antagonists Interaction of GPCR Co-Receptors for HIV.

Structure-Based Development of Antagonists for Chemokine Receptor CXCR4

Structure, Function and Modulation of Chemokine Receptors: Members of the G-Protein-coupled Receptor Superfamily.

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

Molecular Modeling and Site-Directed Mutagenesis of Ccr5 Reveal Residues Critical for Chemokine Binding and Signal Transduction

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

Discovery of Non-Peptide Small Molecular Cxcr4 Antagonists As Anti-Hiv Agents: Recent Advances and Future Opportunities

Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists

Computational Studies of the Binding Modes of Ccr1 Antagonists

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs

Progress in the Research of Small Molecule CCR5 Antagonists

Advances in the Research of Chemokine Receptors Antagonists As Anti-Hiv Agents

Theoretical Studies on the Interactions and Interferences of HIV-1 Glycoprotein Gp120 and Its Coreceptor CCR5

Research and Development of CCR5-targeted Small Molecule Anti-AIDS Drugs

Advances of CCR5 antagonists: From small molecules to macromolecules

Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex

The Molecular Mechanism of Two Coreceptor Binding Site Antibodies X5 and 17b Neutralizing HIV-1: Insights from molecular dynamics simulation.

Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.

Exploring the Stereochemistry of CXCR4-peptide Recognition and Inhibiting HIV-1 Entry with D-peptides Derived from Chemokines.

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.